Nature Reviews Gastroenterology & Hepatology, Published online: 11 November 2026; doi:10.1038/s41575-026-01283-9 With resmetirom and semaglutide approved for non-cirrhotic steatohepatitis with fibrosis, new European guidance moves the question from whether to treat to whom to treat, and with what. The noninvasive, phenotype-driven framework of these guidelines will shape clinical practice, yet much of the recommendations rests on expert consensus rather than comparative or outcome data.
Luis Antonio Díaz, Juan Pablo Arab. Choosing the right drug for the right patient with steatohepatitis. // Nature Reviews Gastroenterology & Hepatology. – 2026. – DOI: 10.1038/s41575-026-01283-9. – URL: https://www.nature.com/articles/s41575-026-01283-9
Luis Antonio Díaz & Juan Pablo Arab (2026). Choosing the right drug for the right patient with steatohepatitis. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01283-9
Luis Antonio Díaz and Juan Pablo Arab. “Choosing the right drug for the right patient with steatohepatitis.” Nature Reviews Gastroenterology & Hepatology, 2026. doi:10.1038/s41575-026-01283-9.
@article{Daz2026,
title = {Choosing the right drug for the right patient with steatohepatitis},
author = {Díaz, Luis Antonio and Arab, Juan Pablo},
journal = {Nature Reviews Gastroenterology \& Hepatology},
year = {2026},
doi = {10.1038/s41575-026-01283-9},
url = {https://www.nature.com/articles/s41575-026-01283-9}
}
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05030-x Comment on: ‘Association of accelerometer-monitored physical activity with incident cataract: epidemiological and genetic evidence’
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05032-9 NAION during incretin-based therapy: an optic nerve head still adapted to hypertension
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05016-9 Comparing refractive errors in CACNA1F and CABP4 -associated disease in a UK cohort
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05018-7 Comment on: ‘Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease’